Chiara Pellizzer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chiara Pellizzer has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Giammona
Istituto di Bioimmagini e Sistemi Biologici Complessi (IBSBC) - National Research Council (CNR), 20054 Segrate, Milan, Italy 2 NBFC, National Biodiversity Future Center, 90133 Palermo, Italy.
1 shared publication - Alessia Lo Dico
Institute of Bioimaging and Biological Complex Systems (IBSBC), National Research Council (CNR), Segrate (MI), Italy
1 shared publication - Bruno Giovanni Galuzzi
National Research Council (CNR) Institute of Bioimaging and Complex Biological Systems (IBSBC) Via F.lli Cervi, 93 , Segrate, 20054
1 shared publication - Clarissa Gervasoni
Istituto di Bioimmagini e Sistemi Biologici Complessi (IBSBC) - National Research Council (CNR), 20054 Segrate, Milan, Italy 2 NBFC, National Biodiversity Future Center, 90133 Palermo, Italy.
1 shared publication - Daniela Gaglio
Istituto di Bioimmagini e Sistemi Biologici Complessi (IBSBC) - National Research Council (CNR), 20054 Segrate, Milan, Italy 2 NBFC, National Biodiversity Future Center, 90133 Palermo, Italy.
1 shared publication - Daniele Capitanio
Department of Biomedical Sciences for Health, University of Milan, 20133 Milan, Italy
1 shared publication
Latest Publications
- Open Access
Disrupting Pregnane X Receptor Signaling Overcomes Temozolomide Resistance in Glioblastoma via Succisa pratensis Derived Metabolites
Glioblastoma remains a highly aggressive and therapy-resistant brain tumor, with limited benefit from the current standard-of-care regimen combining surgery, radiotherapy, and temozolomide. Overcoming chemoresistance therefore represents a critical unmet clinical need. Here, we investigate the anticancer potential of Succisa pratensis and its ability to enhance TMZ efficacy in GBM models. Treatment with S. pratensis markedly reduced cell proliferation and migration while significantly increasing sensitivity to TMZ. Integrated multi-omics analyses revealed extensive metabolic rewiring, characterized by suppression of central carbon metabolism and activation of stress-adaptive pathways. Mechanistically, we identify the Pregnane X Receptor, a key regulator of drug metabolism and chemoresistance, as a central node affected by treatment. Although S. pratensis increased PXR expression, this was not accompanied by induction of canonical downstream targets, including MDR1 and ALDH1A1, indicating a functional impairment of PXR transcriptional activity. Consistently, pharmacological inhibition of PXR using the antagonist SPA70 further potentiated the cytotoxic effects of S. pratensis and TMZ. Docking analyses suggest that specific secondary metabolites, including apigenin-derived compounds, may interact with the PXR ligand-binding domain, providing a potential molecular basis for this effect. Collectively, our findings indicate that S. pratensis enhances TMZ efficacy by inducing metabolic vulnerability and functionally impairing PXR signaling. These results highlight the therapeutic potential of plant-derived metabolites as adjuvant strategies to overcome chemoresistance in glioblastoma.
Open AccessDisrupting Pregnane X Receptor Signaling Overcomes Temozolomide Resistance in Glioblastoma via Succisa pratensis Derived Metabolites
Glioblastoma remains a highly aggressive and therapy-resistant brain tumor, with limited benefit from the current standard-of-care regimen combining surgery, radiotherapy, and temozolomide. Overcoming chemoresistance therefore represents a critical unmet clinical need. Here, we investigate the anticancer potential of Succisa pratensis and its ability to enhance TMZ efficacy in GBM models. Treatment with S. pratensis markedly reduced cell proliferation and migration while significantly increasing sensitivity to TMZ. Integrated multi-omics analyses revealed extensive metabolic rewiring, characterized by suppression of central carbon metabolism and activation of stress-adaptive pathways. Mechanistically, we identify the Pregnane X Receptor, a key regulator of drug metabolism and chemoresistance, as a central node affected by treatment. Although S. pratensis increased PXR expression, this was not accompanied by induction of canonical downstream targets, including MDR1 and ALDH1A1, indicating a functional impairment of PXR transcriptional activity. Consistently, pharmacological inhibition of PXR using the antagonist SPA70 further potentiated the cytotoxic effects of S. pratensis and TMZ. Docking analyses suggest that specific secondary metabolites, including apigenin-derived compounds, may interact with the PXR ligand-binding domain, providing a potential molecular basis for this effect. Collectively, our findings indicate that S. pratensis enhances TMZ efficacy by inducing metabolic vulnerability and functionally impairing PXR signaling. These results highlight the therapeutic potential of plant-derived metabolites as adjuvant strategies to overcome chemoresistance in glioblastoma.